Pharmacokinetics, Safety, and Tolerability of (R)-Ketamine Hydrochloride Injection, a Novel Rapid-Acting Antidepressant, in Healthy Chinese Subjects

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 18; no. 7; p. 1079
• Main Authors: Wang, Rui, Yang, Yuqian, Zhou, Tong, Zou, Bingjie, Ding, Li
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21.07.2025; MDPI
• Subjects: (R)-ketamine; (R)-norketamine; Antidepressants; Body mass index; Cohort analysis; Dosage and administration; Drug dosages; Drug therapy; Electroconvulsive therapy; Hallucinations; Ketamine; Major depressive disorder; N-methyl-D-aspartate receptor antagonist; Patient outcomes; Pharmaceutical research; Pharmacokinetics; Physiological aspects; Pilot projects; Plasma; safety; Side effects; Suicidal behavior; Suicidal ideation; Suicides & suicide attempts; treatment-resistant depression; China; pharmacokinetics; treatment-resistant depression; (R)-norketamine; N-methyl-D-aspartate receptor antagonist; (R)-ketamine; safety

Objectives: (R)-ketamine hydrochloride injection is a novel, rapid-acting antidepressant for the treatment of treatment-resistant depression. The aim of this study was to assess the pharmacokinetics, safety, and tolerability of (R)-ketamine hydrochloride injection in healthy Chinese subjects followi...